Jawed Akhter, Perwez Bakht, Rinki Gupta, Ranjana Pathania
{"title":"Unveiling the Antibacterial Efficacy of a Benzonitrile Small Molecule, IITR00210, in <i>Shigella</i> Infection.","authors":"Jawed Akhter, Perwez Bakht, Rinki Gupta, Ranjana Pathania","doi":"10.1021/acsinfecdis.4c00428","DOIUrl":null,"url":null,"abstract":"<p><p>The escalating prevalence of bacterial infections and the rapid emergence of multidrug-resistant Gram-negative bacterial pathogens highlight an urgent demand for effective antibacterial agents. In this study, we report our findings on IITR00210, a small molecule belonging to the nitrile class. The small molecule demonstrates broad-spectrum activity against bacterial pathogens, specifically against enteric pathogens, and exhibits antibiofilm activity. IITR00210 displays potent bactericidal activity against enteropathogens, resulting in a reduction of bacterial counts greater than 3 Log<sub>10</sub> CFU in time-kill kinetic assays. Mechanistic investigations revealed that IITR00210 induces bacterial cell envelope stress, leading to the alteration of the overall proton motive force (PMF). The disruption of PMF causes intracellular ATP dissipation and ultimately promotes cell death. The cell envelope stress generated in the presence of IITR00210 leads to a translational aberration. Importantly, IITR00210 exhibits a safe profile in <i>in vitro</i> and <i>in vivo</i> settings. The small molecule further showed potent intracellular antibacterial activity in polymorphonuclear cells infected with enteric pathogens and antiadhesion activity in mammalian cell lines. IITR00210 proves to be a promising therapeutic candidate, displaying a lack of stable resistance development, and it exhibited efficacy in the treatment of bacterial infections in a shigellosis murine model.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c00428","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The escalating prevalence of bacterial infections and the rapid emergence of multidrug-resistant Gram-negative bacterial pathogens highlight an urgent demand for effective antibacterial agents. In this study, we report our findings on IITR00210, a small molecule belonging to the nitrile class. The small molecule demonstrates broad-spectrum activity against bacterial pathogens, specifically against enteric pathogens, and exhibits antibiofilm activity. IITR00210 displays potent bactericidal activity against enteropathogens, resulting in a reduction of bacterial counts greater than 3 Log10 CFU in time-kill kinetic assays. Mechanistic investigations revealed that IITR00210 induces bacterial cell envelope stress, leading to the alteration of the overall proton motive force (PMF). The disruption of PMF causes intracellular ATP dissipation and ultimately promotes cell death. The cell envelope stress generated in the presence of IITR00210 leads to a translational aberration. Importantly, IITR00210 exhibits a safe profile in in vitro and in vivo settings. The small molecule further showed potent intracellular antibacterial activity in polymorphonuclear cells infected with enteric pathogens and antiadhesion activity in mammalian cell lines. IITR00210 proves to be a promising therapeutic candidate, displaying a lack of stable resistance development, and it exhibited efficacy in the treatment of bacterial infections in a shigellosis murine model.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.